
## Victor Pantea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12033936/publications.pdf Version: 2024-02-01



| # | Article   | IF  | CITATIONS |
|---|---|-----|-----------|
| 1 | Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with<br>chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised,<br>open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 877-889. | 8.1 | 191       |
| 2 | Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon<br>Alfa-2a in Patients With Chronic HBV Infection NaÃ⁻ve to Nucleos(t)ide Therapy. Gastroenterology,<br>2020, 158, 2180-2194.  | 1.3 | 154       |
| 3 | Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139 a and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection. Hepatology Communications, 2021, 5, 189-202.  | 4.3 | 62        |
| 4 | Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Scientific Reports, 2020, 10, 7837.   | 3.3 | 24        |
| 5 | Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAPâ€Based<br>Therapy. Hepatology Communications, 2021, 5, 1873-1887.   | 4.3 | 12        |
| 6 | Benefit of transaminase elevations in establishing functional cure of HBV infection during napâ€based combination therapy. Journal of Viral Hepatitis, 2021, 28, 817-825.   | 2.0 | 10        |
| 7 | HBsAg isoform dynamics during NAPâ€based therapy of HBeAgâ€negative chronic HBV and HBV/HDV<br>infection. Hepatology Communications, 2022, 6, 1870-1880.  | 4.3 | 10        |